AI Text Messaging for Cardiovascular Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how well three types of text messaging can manage cardiovascular disease risk factors in underserved communities. The study tests simple text messages, interactive chatbot messages, and chatbot messages with added pharmacist support to determine which method best aids adherence to lifestyle changes and medications. The goal is to improve health outcomes for individuals with high blood pressure, diabetes, or high cholesterol, particularly those struggling with medication adherence. Participants should have one of these conditions at a risky level and have recently faced challenges in refilling prescriptions. The findings could guide better patient involvement in managing chronic cardiovascular diseases. As an unphased trial, this study offers participants the chance to contribute to innovative solutions for managing cardiovascular health in underserved communities.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the study focuses on improving medication adherence, it is likely that you will continue your current medications.
Is there any evidence suggesting that this trial's strategies are likely to be safe?
Research shows that AI text messaging, including simple texts, interactive chatbot messages, and those with pharmacist support, is generally safe for people. Current studies have not identified any major negative effects from these methods. These tools aim to help people manage their heart health by sending reminders and tips to their phones.
Evidence from earlier studies indicates that people find AI health reminders easy to use. Many appreciate the convenience of receiving health prompts in this manner. Although this approach is not a medication or medical procedure, it helps improve health habits and outcomes by encouraging actions like checking blood pressure or making healthier lifestyle choices.
Overall, these digital tools are designed to help people manage their health and are considered safe. They offer a modern way to support individuals, especially those in underserved communities, in maintaining better health without causing harm.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores innovative ways to support people with cardiovascular disease using AI-driven text messaging. Unlike standard care, which typically involves medication and lifestyle changes, this approach leverages technology to engage patients in their own care. The first arm uses generic text messages from trusted sources to remind patients of tasks like checking their blood pressure. The second arm goes a step further with an interactive AI chatbot that uses natural language processing to create personalized and engaging conversations, encouraging patients to take active steps in managing their health. The third arm combines this AI chatbot with proactive pharmacist management, offering a more comprehensive approach by addressing individual risk factors through direct communication. This trial aims to find out if these tech-driven strategies can enhance patient autonomy and improve cardiovascular health outcomes.
What evidence suggests that this trial's strategies could be effective for improving cardiovascular risk factors in patients facing health disparities?
Research has shown that AI text messaging, such as interactive chatbot messages, can help manage heart health risks. For example, one study found that these chatbots increased awareness and knowledge about heart health, potentially leading to better self-care. Another study suggested that AI messaging encouraging heart-healthy habits could help control risk factors.
In this trial, participants may receive either generic text messages or interactive AI chatbot text messaging. Some participants will also receive proactive pharmacist management alongside the AI chatbot messaging. Research has demonstrated that pharmacists play a key role in reducing heart health risks. This method combines mobile technology and expert support to focus on lifestyle changes and adherence to medication plans, aiming to improve overall heart health.56789Who Is on the Research Team?
Michael Ho, MD, PhD
Principal Investigator
University of Colorado, Denver
Are You a Good Fit for This Trial?
This trial is for patients with cardiovascular risk factors who face health disparities, such as ethnic minorities, those with limited English proficiency, and low-income individuals. The study aims to improve self-management of chronic diseases in these groups.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Development and Pilot
Development of AI chatbot infrastructure and pilot study to assess feasibility
Randomized Intervention
Conduct a pragmatic patient-level randomized intervention of 3 text messaging delivery strategies for self-management support of CV risk factors
Follow-up
Participants are monitored for changes in Life's Essential 8 health score and other secondary outcomes
What Are the Treatments Tested in This Trial?
Interventions
- AI Text Messaging
Trial Overview
The trial compares three strategies to reduce cardiovascular disease risks: generic text messages, interactive AI chatbot messaging, and chatbot messages plus proactive pharmacist support. It uses the AHA's Life's Essential 8 metrics for evaluation.
How Is the Trial Designed?
The information content for these messages will be derived from trusted sources of medical information and contain links to websites such as American Heart Association. An example of such a message would be: Remember to take your blood pressure today! You can find more information from the American Heart Association by clicking here. Patients will be able to return texts with questions which will be addressed by the study team, including a clinical pharmacist if needed.
This AI system will utilize NLP and ML to facilitate bi-directional system-patient dialogue with messages that incorporate content utilizing tailoring, behavioral nudges and persuasive messaging as described above. An example message would be: Make a promise to yourself to check your blood pressure today! Your goal is to have the top number at 120 or lower and the bottom number at 80 or lower. Each message will end with a question for the participant that will encourage engagement with the AI conversational chatbot that allows greater opportunity to use theoretical content to engage patient autonomy, competence and relatedness, the mechanisms through which we will impact behaviors.
The AI chatbot will be the same as arm 2 (Interactive AI chatbot text messaging alone). In this arm, however, pharmacists will review patient's baseline LE8 risk factors and proactively contact patients via telephone and/or the EHR patient portal to address any risk factor that is in poor/intermediate health categories. The investigators are proposing proactive pharmacist involvement as a population-based approach to address patients with uncontrolled CV risk factors.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Published Research Related to This Trial
Citations
AI HeartBot to Increase Women's Awareness and ...
This study aimed to evaluate the potential efficacy of HeartBot to increase women's awareness and knowledge of heart attack symptoms and care- ...
Human-Delivered Conversation Versus AI Chatbot ...
This study aims to evaluate and explore the potential efficacy of human-delivered conversations versus AI chatbot conversations in increasing ...
Effect of Text Messaging on Risk Factor Management in ...
Text messages supporting secondary prevention among patients with coronary heart disease did not lead to a greater reduction in blood pressure ...
4.
dcricollab.dcri.duke.edu
dcricollab.dcri.duke.edu/sites/NIHKR/KR/Chat%204%20Heart%20Health%20Study%20Snapshot.pdfUsing AI Text Messaging to Improve the American Heart ...
The goal of Chat 4 Heart Health is to improve control of risk factors for cardiovascular disease using a multilevel intervention that leverages mobile phone– ...
5.
centerwatch.com
centerwatch.com/clinical-trials/listings/NCT06324981/using-ai-text-messaging-to-improve-ahas-lifes-essential-8-health-behaviors?state=CO&city=WheatridgeUsing AI Text Messaging to Improve AHA's Life's Essential ...
Patients with CV disease risk factors will be randomized to 1 of 3 automated communication approaches: 1) generic text messages; 2) interactive ...
Using AI Text Messaging to Improve AHA's Life's Essential 8 ...
The three different strategies are: 1) text messages, 2) interactive chatbot messages, and 3) chatbot messages with proactive pharmacist support. To measure ...
7.
rethinkingclinicaltrials.org
rethinkingclinicaltrials.org/demonstration-projects/using-artificially-intellegent-text-messaging-technology-to-improve-aha-le8-health-behaviors/UH3 Project: Using Artificially Intelligent Text Messaging ...
The goal of Chat 4 Heart Health is to improve control of risk factors for cardiovascular disease using a multilevel intervention that leverages mobile phone– ...
Study Protocol “Using artificially intelligent text messaging ...
Our goal is to improve control of cardiovascular (CV) disease risk factors using a multilevel intervention leveraging cellphone-based text ...
9.
dcricollab.dcri.duke.edu
dcricollab.dcri.duke.edu/sites/NIHKR/KR/Chat%204%20Heart%20Health%20Ethics%20and%20Regulatory%20Discussion.pdfChat 4 Heart Health Ethics and Regulatory Discussion
generic and AI chatbot text message and proactive pharmacist support interventions. PRISM includes the RE-. AIM outcomes identified above and ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.